France's Medical Cannabis Law Nears Its Final Hurdle

France's permanent medical cannabis framework is reportedly close to becoming law. According to Paris-based market consultancy Augur Associates, the last outstanding text, the reimbursement decree, has reached the Conseil d'État and is now under review, with sign-off expected in the coming weeks. If that holds, first prescriptions under the new system could plausibly begin in Q1 2027.

This matters because the reimbursement decree is the final regulatory step. Until it is published, France remains stuck in an extended pilot. After publication, companies can start formal regulatory submissions. Augur stresses one caveat. Its sources are "several sources close to the process," and the government has not publicly confirmed this procedural status. The firm says it should be treated as informed market intelligence, not official fact.

From Pilot to Permanent: France's Two-Part Framework

France has been testing medical cannabis through a state-run pilot since March 2021. The pilot is a controlled experiment, overseen by the national medicines regulator, that lets a limited number of patients access cannabis-based medicines through selected hospitals and doctors. It was always meant to be temporary. The goal was to gather evidence before building a permanent system.

That permanent system rests on two regulatory packages:

• The authorisation package. This is the core decree for the ANSM, the Agence nationale de sécurité du médicament et des produits de santé, which is France's national medicines regulator. It comes with two orders, one covering product specifications and one covering cultivation.
• The reimbursement decree. This regulatory text sets out how France's national health insurance system will pay for prescribed cannabis medicines.

The first package cleared Conseil d'État review in July 2026. The Conseil d'État is France's highest administrative court, and it also advises the government on draft regulations before they are adopted. In the same month, the package completed the EU's technical notification procedure. Under that mechanism, member states notify the European Commission and other EU countries of draft technical rules before adopting them.

On January 21, 2026, the French government had already confirmed that the main decree had the Council's approval. Publishing it would allow the ANSM to begin processing applications. However, the government tied the timing of publication to the reimbursement text.

How the Reimbursement Decree Reached the Conseil d'État

The reimbursement decree has taken a longer route than officials first suggested. On June 30, 2026, the government told the French Senate four things:

• the text had been finalised in mid-June
• the Ministry of Economy and Finance had validated it
• it would be sent to the Conseil d'État that same day
• publication was expected after the summer recess

Augur's October 2026 white paper, France Medical Cannabis: Regulatory Progress & Market Entry Outlook, now places the decree at the Conseil d'État. The table below sets out the key milestones.

Why France's Timetable Slipped

The government said in June that the reimbursement decree would be sent to the Conseil d'État immediately. That did not happen as quickly as announced. Augur's report puts it plainly:

"The decree has progressed substantially during 2026, but its route through the final administrative stages has taken longer than the timetable announced by the government in June suggested."

According to Augur's sources, the draft first went through the CNAM, the Caisse nationale de l'Assurance Maladie, which is the national fund that runs France's public health insurance. Only after that did it reach the Conseil d'État. This step is not a red flag. French law requires this kind of consultation for social-security measures, and a decree that sets reimbursement rules falls squarely into that category.

Two other factors added time:

• The summer recess. French administrative activity slows sharply over the summer, and that pause fell in the middle of the decree's journey.
• A change of personnel. On July 6, 2026, Mickaël Benzaqui was appointed health adviser to the prime minister. Changes in advisory roles often mean files are reviewed again before they move forward.

None of these factors points to political resistance. They point to procedure. Reimbursement decrees touch public money, so they pass through more administrative checkpoints than a standard regulatory order. Each checkpoint adds weeks.

What the HAS Delay Means for First Prescriptions

The next major gatekeeper after publication is the HAS, the Haute Autorité de Santé. The HAS is France's independent health technology assessment body. It evaluates medical products and advises on whether and how they should be reimbursed. HAS hearings set for October 20 and 21, 2026, were postponed in September. According to Augur, they were postponed because the regulatory decree needed for that stage had not yet been published.

Augur still considers a Q1 2027 start for first prescriptions plausible. That date depends on several steps happening in order:

1. The Conseil d'État completes its review of the reimbursement decree.
2. The decree is signed.
3. The decree is published in the official journal.
4. The HAS sets and runs its evaluation timetable.

Any delay at one step pushes back every step after it. For that reason, Augur advises operators to plan against a timetable range rather than a single launch date. We think that is sound advice for anyone working in regulated cannabis. Hard deadlines in this industry tend to move, while preparation keeps its value whatever the date turns out to be.

Which Conditions France Will Cover

The therapeutic scope of the permanent framework has not changed since the draft presented at Cannabis Europa Paris in February 2026. Five indications are included:

• Refractory neuropathic pain. Nerve-related pain is called "refractory" when it does not respond adequately to standard treatments.
• Pharmacoresistant epilepsy. This is epilepsy in which seizures continue despite trials of appropriate anti-seizure medications.
• Painful spasticity. This covers spasticity linked to multiple sclerosis or other central nervous system disorders.
• Refractory oncology symptoms. These are cancer-related symptoms that conventional care cannot control.
• Advanced palliative situations. This covers refractory symptoms in patients receiving end-of-life care.

Every indication has the same thing in common: cannabis is positioned as a treatment for when other options have failed, not as a first-line therapy. The list is deliberately narrow and clinically tight. It mirrors the pilot's original focus, which keeps continuity for doctors and patients already familiar with the programme.

For operators, this scope affects everything from clinical data packages to how products are presented to prescribers. A product built around a broad wellness claim has no place here. A product backed by consistent dosing and solid evidence for these specific conditions does.

France's Product Rules: Pharmaceutical, Not Flower

France's framework is built around pharmaceutical-grade formats, and the product rules show it. Three cannabinoid profiles are recognised:

• Delta-9-THC dominant. Delta-9-THC is the main intoxicating compound in cannabis.
• Balanced THC/CBD. These products contain roughly equal amounts of both cannabinoids.
• CBD dominant. CBD, or cannabidiol, is a non-intoxicating cannabinoid studied for its therapeutic potential.

Three further rules complete the picture:

• Raw dried flower is not intended to be admitted.
• Fast-acting formats will only be considered in secure, tamper-proof, non-refillable single-dose cartridges.
• Inhaled administration is expected to rely on a dedicated CE-marked medical device. A CE mark shows that a device meets EU safety and performance requirements.

As growers, we will say it straight: France's medical system is not designed around the bud. Germany's market leans heavily on flower, but France has chosen tight dosing control and tamper-proof formats instead. Augur's recommendation follows from that choice. Operators should treat France as a product-by-product regulatory mapping exercise rather than a generic market-access operation. Each product format, cannabinoid profile and delivery device needs to be checked against the rules on its own terms.

How Big Could France's Medical Cannabis Market Be?

The pilot itself is shrinking. Participation fell from 1,849 patients in September 2024 to an estimated 700, as the programme was extended repeatedly without a permanent replacement. The potential market under the permanent framework is much larger. Estimates vary widely depending on the source:

• Patient organisations: roughly 100,000 people potentially eligible for treatment.
• Parliamentary discussion: 150,000 to 300,000 patients in "therapeutic impasse," meaning patients for whom existing treatments have run out.
• Augur's 2025 projection: about 100,000 reimbursed patients by 2030, potentially growing three to four times by 2035. That would imply something in the region of 300,000 to 400,000 patients.

The gap between around 700 pilot patients today and six-figure projections shows how much demand the pilot has not served. That opportunity, however, is limited to operators whose product range fits France's pharmaceutically minded framework. Volume will come from reimbursed prescriptions for tightly defined conditions, not from open retail access.

Augur's report closes with a reminder that publication is a beginning, not a finish line:

"Publication will not mark the beginning of the market-entry process. It will mark the point at which companies can move from preparation to formal regulatory submissions."

Quality, transparency and patience will matter more than speed. Companies with their documentation ready on publication day will be best placed when France opens.

Frequently asked questions

What is France's medical cannabis reimbursement decree?

The reimbursement decree is the regulatory text that sets out how France's national health insurance will pay for prescribed cannabis-based medicines. It is the second of two packages needed to replace the pilot with a permanent framework. Until it is published, the ANSM cannot fully begin processing product applications under the new rules.

When could patients in France get prescriptions under the new framework?

Augur Associates considers a first quarter 2027 start plausible. That timing depends on the Conseil d'État finishing its review, the decree being signed and published, and the Haute Autorité de Santé completing its evaluation. Because each step depends on the one before it, the consultancy recommends planning around a timetable range.

Will dried cannabis flower be allowed in France's medical programme?

No. Raw dried flower is not intended to be admitted under France's permanent framework. The system favours pharmaceutical-style formats instead. Fast-acting products must come in secure, tamper-proof, single-dose cartridges that cannot be refilled, and inhaled use is expected to require a dedicated CE-marked medical device.

Which medical conditions qualify for cannabis treatment in France?

Five indications are covered: refractory neuropathic pain, pharmacoresistant epilepsy, painful spasticity linked to multiple sclerosis or other central nervous system disorders, refractory cancer-related symptoms, and advanced palliative situations. In each case, cannabis is intended for patients whose symptoms have not responded adequately to standard treatments.

How many patients could France's permanent framework eventually serve?

Estimates range widely. Patient groups cite around 100,000 potentially eligible people, while parliamentary debate has mentioned 150,000 to 300,000 patients with no remaining treatment options. Augur projected about 100,000 reimbursed patients by 2030, with possible growth of three to four times that figure by 2035.

Has the French government confirmed the decree is at the Conseil d'État?

Not publicly. The report that the reimbursement decree is under Conseil d'État review comes from Augur Associates, citing several sources close to the process. The consultancy itself describes this status as informed market intelligence rather than official confirmation, so it should be read with appropriate caution.